OVERVIEW
Stocktwits Top 25 Week 17

Welcome to the Stocktwits Top 25 Newsletter for Week 17 of 2024!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. 

Here are the Stocktwits Top 25 Lists for Week 17:

P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

S&P 500
ST Top 25 S&P 500

The S&P 500 Top 25 list (+7.53%) outperformed the S&P 500 index (+2.67%).

There were 8 major changes to the list this week.

Check out how the momentum meter has performed vs. the S&P 500 index.

STOCKTWITS EDGE
Elevate Your Trading Game 👀

Unleash your trading potential with our new Edge subscription plan—featuring unique social data, an ad-free experience, and more!

NASDAQ 100
The Large-Cap Nasdaq 100

The Nasdaq 100 Top 25 list (+6.34%) outperformed the Nasdaq 100 index (+3.99%).

There were 4 major changes to the list this week.

RUSSELL 2000
The Growth-Centric Russell 2000

The Russell 2000 Top 25 list (+10.98%) outperformed the Russell 2000 index (+2.79%).

There were 4 major changes to the list this week.

Top Dawg Of The Week 🐶

The Top 25 lists' Top Dawg was Cullinan Therapeutics, which rallied 61.56%. 📈

The small-cap biotech company focuses on developing oncology therapies for cancer patients in the U.S. More broadly, the small and mid-cap biotech space remains in focus as investors look for the next “takeover target” big pharma will tap to grow their pipelines. 🕵️

There was no specific news about the stock this week. Instead, the momentum continued following the prior week's news of its strategic expansion into autoimmune diseases and an oversubscribed $280 million private placement. 📰

$CGEM is up 148.28% YTD.

Get In Touch

Follow our social channels for great, real-time content on Stocktwits and Twitter. And check out our YouTube channel for in-depth video content! 📲

Help us deliver the best content possible by completing this brief survey. 📝

Email me (Tom Bruni) your feedback; I’d love to hear from you. 📧

Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here. 👍

Disclaimer: Content, news, research, tools, and securities symbols are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍